ArticleClinical ophthalmology (Auckland, N.Z.)2026
Preoperative Use of the Rho Kinase Inhibitor Ripasudil Protects the Corneal Endothelium from Trabeculectomy-Induced Damage.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Rho kinase inhibitors have emerged as treatment options for glaucoma and corneal endothelial disorders. Ripasudil, a Rho kinase inhibitor, has been approved for clinical use in glaucoma; however, further investigations are warranted for its use in the treatment of corneal endothelial disorders. We aimed to evaluate the effectiveness of preoperative ripasudil in reducing corneal endothelial damage following trabeculectomy. Patients and Methods: This retrospective observational study included a total of 139 consecutive eyes with primary open-angle glaucoma that underwent trabeculectomy; of these, 68 underwent trabeculectomy alone, whereas 71 underwent trabeculectomy combined with phacoemulsification and intraocular lens implantation. A total of 67 eyes were treated with 0.4% ripasudil eye drops twice daily for >3 months until the day before trabeculectomy (ripasudil group). The remainder did not receive preoperative ripasudil (without-ripasudil group). No patients received ripasudil postoperatively. The primary measures included changes in corneal endothelial cell density following surgery. The mean follow-up period was 71.6 days. Results: Among the 139 trabeculectomy eyes, the ripasudil group demonstrated a significantly lower mean endothelial cell density loss (-0.16%) than the without-ripasudil group (6.66%) following surgery (p < 0.001). Among the 71 trabeculectomy+phacoemulsification+intraocular lens implantation eyes, the ripasudil group demonstrated a significantly lower mean endothelial cell density loss (0.97%) than the without-ripasudil group (7.70%) following surgery (p < 0.05). Conclusion: Preoperative administration of ripasudil eye drops may help maintain the functional integrity of the corneal endothelium in patients with glaucoma who underwent trabeculectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.